Cannabinoidergic
Cannabinoidergic refers to the biological system that interacts with cannabinoids, a class of chemical compounds that act on cannabinoid receptors in cells that alter neurotransmitter release in the brain. The cannabinoidergic system includes the endocannabinoid system, which consists of endogenous lipid-based retrograde neurotransmitters that bind to cannabinoid receptors, and the enzymes that synthesize and degrade them.
Cannabinoid Receptors
Cannabinoid receptors are a class of cell membrane receptors under the G protein-couple receptors superfamily. They are activated by three major groups of ligands: endocannabinoids, produced by the mammalian body; plant cannabinoids (such as THC, produced by the cannabis plant); and synthetic cannabinoids (like HU-210). There are currently two known types of cannabinoid receptors, termed CB1 and CB2.
CB1
CB1 is expressed mainly in the brain (central nervous system or "CNS"), but also in the lungs, liver and kidneys. CB1 receptors are thought to be one of the most widely expressed Gαi protein-coupled receptors in the brain.
CB2
CB2, on the other hand, is mainly expressed in the immune system and in hematopoietic cells. Recent findings suggest that CB2 may also be expressed in the CNS and could play a role in the therapeutic effects of cannabinoids.
Endocannabinoids
Endocannabinoids, also called endogenous cannabinoids, are molecules made by your body. They're similar to cannabinoids, but they're produced by your body. Experts have identified two key endocannabinoids so far: anandamide (AEA) and 2-arachidonoylglyerol (2-AG).
Pharmacology
Cannabinoids have been used for medicinal purposes for centuries, and in the past decade, attention has been drawn to their broad therapeutic potential particularly in seizure management, neuroprotection, pain relief and inflammation work, and cancer treatment. The pharmacology of cannabinoids appears to be complex, with a variety of mechanisms contributing to the many reported therapeutic features of cannabinoid compounds.
See Also
References
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD